# Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

> **NCT03680521** · PHASE2 · COMPLETED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 25 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Sitravatinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03680521
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-10
- **Primary completion:** 2020-04-27
- **Final completion:** 2023-05-18
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03680521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03680521, "Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03680521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*